Table 1 Demographic and clinical data of the studied patients
Group | P | Sig. | ||||
|---|---|---|---|---|---|---|
PL Group | ACDF Group | |||||
Mean | ± SD | Mean | ± SD | |||
Age | 61.8 | 6.7 | 63.4 | 6.8 | 0.522‡ | NS |
Disease duration (months) | 7.1 | 4.0 | 6.1 | 4.2 | 0.509‡ | NS |
Sex | ||||||
Male | 10 | 66.7% | 10 | 66.7% | 1.0* | NS |
Female | 5 | 33.3% | 5 | 33.3% | ||
Number of affected levels | ||||||
Two | 10 | 66.7% | 8 | 53.3% | 0.456* | NS |
Three | 5 | 33.3% | 7 | 46.7% | ||
Numbness | ||||||
Negative | 5 | 33.3% | 3 | 20.0% | 0.682** | NS |
Positive | 10 | 66.7% | 12 | 80.0% | ||
Heaviness | ||||||
Negative | 2 | 13.3% | 3 | 20.0% | 1.0** | NS |
Positive | 13 | 86.7% | 12 | 80.0% | ||
Upper limb weakness | ||||||
Negative | 2 | 13.3% | 2 | 13.3% | 1.0** | NS |
Positive | 13 | 86.7% | 13 | 86.7% | ||
Lower limb weakness | ||||||
Negative | 6 | 40.0% | 5 | 33.3% | 0.705* | NS |
Positive | 9 | 60.0% | 10 | 66.7% | ||
Sensory loss | ||||||
Negative | 2 | 13.3% | 4 | 26.7% | 0.651** | NS |
Positive | 13 | 86.7% | 11 | 73.3% | ||
Hyperreflexia | ||||||
Negative | 3 | 20.0% | 2 | 13.3% | 1.0** | NS |
Positive | 12 | 80.0% | 13 | 86.7% | ||
Babinski | ||||||
Negative | 6 | 40.0% | 8 | 53.3% | 0.464* | NS |
Positive | 9 | 60.0% | 7 | 46.7% | ||
Hoffmann | ||||||
Negative | 6 | 40.0% | 11 | 73.3% | 0.065* | NS |
Positive | 9 | 60.0% | 4 | 26.7% | ||
Ankle clonus | ||||||
Negative | 11 | 73.3% | 11 | 73.3% | 1.0** | NS |
Positive | 4 | 26.7% | 4 | 26.7% | ||
Cord signal | ||||||
Negative | 5 | 33.3% | 9 | 60.0% | 0.143* | NS |
Positive | 10 | 66.7% | 6 | 40.0% | ||
Sphincteric disturbance | ||||||
Negative | 9 | 60.0% | 8 | 53.3% | 0.713* | NS |
Positive | 6 | 40.0% | 7 | 46.7% | ||